[Market Focus] The BioMed Rises on AI and COVID-19 Concerns... 'Diagnostic Technology in Spotlight'

As highly pathogenic avian influenza (AI) resurges both domestically and internationally, with concerns now being raised about the possibility of human infection, interest in diagnostic technology is growing. The BioMed is experiencing an upward trend. The BioMed is currently developing a highly sensitive PCR-based AI diagnostic kit that can be applied to avian, mammalian, and human samples.

As of 10:05 a.m. on May 22, The BioMed was trading at 8,150 won, up 1,630 won (25.00%) from the previous trading day.

Following the recent launch of its new management team, The BioMed has been accelerating the development of AI diagnostic technology. The company is attracting market attention for its rapid and accurate molecular diagnostic technology, especially as mutations of highly pathogenic AI viruses continue to occur.

In addition, concerns about a resurgence of COVID-19 are intensifying, particularly in Asia. In Hong Kong, the number of COVID-19 deaths reached 30 over the past four weeks, marking the highest level in a year. In Thailand, the number of confirmed cases this week surged to 33,030, more than doubling compared to the previous week.